concept

RB

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about RB: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

2519Connections

26Hypotheses

0Analyses

50Outgoing

50Incoming

2Experiments

0Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	RB
Linked Hypotheses	5 hypotheses

Wiki Pages (20)

Knowledge base pages for this entity

Pathway Diagram

graph TD
    RB["RB"]
    style RB fill:#1a237e,stroke:#4fc3f7,stroke-width:3px
    RB -->|"interacts"| Als["Als"]
    RB -.->|"inhibits"| Atherosclerosis["Atherosclerosis"]
    RB -->|"activates"| Dementia["Dementia"]
    RB -->|"activates"| Alzheimer["Alzheimer"]
    RB -->|"interacts"| Frontotemporal_Dementia["Frontotemporal Dementia"]
    RB -->|"interacts"| Parkinson["Parkinson"]
    MTOR([MTOR]) -.->|"inhibits"| RB
    AMPK([AMPK]) -->|"interacts"| RB
    ABCA1([ABCA1]) -->|"interacts"| RB
    P2RY12([P2RY12]) -.->|"inhibits"| RB
    ABCG1([ABCG1]) -->|"interacts"| RB
    ALS([ALS]) -->|"interacts"| RB
    MAO([MAO]) -.->|"inhibits"| RB
    ULK1([ULK1]) -->|"interacts"| RB
    ATP([ATP]) -->|"interacts"| RB
    ACTB([ACTB]) -->|"interacts"| RB

Outgoing (446)

Target	Relation	Type	Str
Schizophrenia	interacts_with	disease	0.60
Pyroptosis	expressed_in	disease	0.60
Ferroptosis	interacts_with	disease	0.60
Stroke	protects_against	disease	0.60
Cancer	associated_with	disease	0.60
Diabetes	expressed_in	disease	0.60
Fibrosis	causes	disease	0.60
Autism	regulates	disease	0.60
Vascular Dementia	activates	disease	0.60
Senescence	activates	disease	0.60
Tauopathy	regulates	disease	0.60
Glioblastoma	causes	disease	0.60
Amyotrophic Lateral Sclerosis	associated_with	disease	0.60
Parkinson	associated_with	disease	0.60
Epilepsy	activates	disease	0.60
Neurodegeneration	expressed_in	disease	0.60
Ischemia	regulates	disease	0.60
Parkinson	inhibits	disease	0.60
Als	activates	disease	0.60
Fibrosis	inhibits	disease	0.60
Autism	expressed_in	disease	0.60
Dementia	activates	disease	0.60
Neuroinflammation	expressed_in	disease	0.60
Lewy Body	activates	disease	0.60
Cancer	inhibits	disease	0.60
Epilepsy	interacts_with	disease	0.60
Dementia	interacts_with	disease	0.60
Spinal Muscular Atrophy	regulates	disease	0.60
Frontotemporal Dementia	interacts_with	disease	0.60
Neuroinflammation	associated_with	disease	0.60
Parkinson	interacts_with	disease	0.60
Ptsd	inhibits	disease	0.60
Alzheimer	interacts_with	disease	0.60
Huntington	therapeutic_target	disease	0.60
Cancer	causes	disease	0.60
Ischemia	expressed_in	disease	0.60
Aging	protects_against	disease	0.60
Aging	expressed_in	disease	0.60
Dementia	expressed_in	disease	0.60
Tauopathy	expressed_in	disease	0.60
Frontotemporal Dementia	activates	disease	0.60
Cerebral Amyloid Angiopathy	activates	disease	0.60
Neurodegeneration	activates	disease	0.60
Pyroptosis	causes	disease	0.60
Fibrosis	therapeutic_target	disease	0.60
Tauopathy	activates	disease	0.60
Alzheimer	activates	disease	0.60
Ischemia	associated_with	disease	0.60
Cancer	activates	disease	0.60
Als	interacts_with	disease	0.60

Incoming (2073)

Source	Relation	Type	Str
MTOR	inhibits	gene	0.60
ABCA1	interacts_with	gene	0.60
P2RY12	inhibits	gene	0.60
ABCG1	interacts_with	gene	0.60
ULK1	interacts_with	gene	0.60
ACTB	interacts_with	gene	0.60
ATG5	interacts_with	gene	0.60
APOA1	interacts_with	gene	0.60
SQSTM1	interacts_with	gene	0.60
AQP4	associated_with	gene	0.60
SPP1	activates	gene	0.60
C1QA	activates	gene	0.60
GRN	activates	gene	0.60
CTSB	activates	gene	0.60
PTEN	interacts_with	gene	0.60
TAX1BP1	interacts_with	gene	0.60
PRKN	interacts_with	gene	0.60
CTSD	interacts_with	gene	0.60
BECN1	interacts_with	gene	0.60
PEX3	interacts_with	gene	0.60
PARKIN	interacts_with	gene	0.60
SNCA	interacts_with	gene	0.60
SESN2	interacts_with	gene	0.60
STING1	interacts_with	gene	0.60
CAT	interacts_with	gene	0.60
BCL2	interacts_with	gene	0.60
LMNA	interacts_with	gene	0.60
ABCD3	interacts_with	gene	0.60
EMD	interacts_with	gene	0.60
NBR1	interacts_with	gene	0.60
RB1	interacts_with	gene	0.60
OPTINEURIN	interacts_with	gene	0.60
AMBRA1	interacts_with	gene	0.60
G3BP1	interacts_with	gene	0.60
NLRP3	interacts_with	gene	0.60
ATM	interacts_with	gene	0.60
OPTN	interacts_with	gene	0.60
GBA	interacts_with	gene	0.60
MUL1	interacts_with	gene	0.60
DISC1	interacts_with	gene	0.60
RTN3	interacts_with	gene	0.60
UBIQUITIN	interacts_with	gene	0.60
FUNDC1	interacts_with	gene	0.60
SNCAIP	interacts_with	gene	0.60
CANX	interacts_with	gene	0.60
PARL	interacts_with	gene	0.60
BCL2L13	interacts_with	gene	0.60
PHB2	interacts_with	gene	0.60
BNIP3	interacts_with	gene	0.60
NTN1	interacts_with	gene	0.60

Targeting Hypotheses (26)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
RBM45 Liquid-Liquid Phase Separation Dominance Hijacks RNA P	0.868	als	-
Vicious Cycle Hypothesis: Cholinergic Dysfunction Exacerbate	0.785	-	Do β-amyloid plaques and neurofibrillary
Aryl Hydrocarbon Receptor (AHR) Activation in B Cells Determ	0.738	neuroinflammation	How do B cells mechanistically orchestra
VPS35 Retromer Dysfunction Creates a GCase Trafficking Bottl	0.700	neurodegeneration	-
AQP4-Dependent Astrocyte Swelling Exacerbates Excitotoxic Ne	0.670	neurodegeneration	What are the specific molecular mechanis

Vascular mural cell degeneration precedes and exacerbates pa	0.661	alzheimers	SEA-AD Single-Cell Analysis: Cell-Type V
early PD proteogenomic hubs that are both causal enough and	0.626	neurodegeneration	Proteogenomic Network Hubs as Druggable
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	m6A RNA Modification and Alpha-Synuclein
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Cell-Autonomous vs Non-Cell-Autonomous M
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Sex-Specific Microglial States in Amyloi
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Genetic Aging Landscape Variants and Epi
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	DPP6 GWAS Signal: Cell-Type Regulatory N
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Causal Sequence of TDP-43 Nuclear Cleara
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Proteogenomic Network Hubs as Druggable
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Biophysical Determinants Shifting FUS/TD
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	VEGF Family GWAS Signals and Cerebrovasc
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	CCL2-CCR2 Axis at NMJ: Mechanism of Sele
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Non-Neuronal Transcriptional Changes Pre
Aryl Hydrocarbon Receptor (AhR) Activation by Microbiome Met	0.597	neuroinflammation	What molecular mechanisms determine whet
Parthenolide perturbs adenosine transport or metabolism upst	0.506	neuropharmacology	How does parthenolide specifically modul
REV-ERB Agonist Microglial Deactivation	0.455	chronobiology	Can circadian interventions reverse micr
Phosphatidylserine Decarboxylase (PISD) Restoration to Corre	0.342	lipidomics	Lipid metabolism dysregulation in Alzhei
Astrocyte-Neuron Lactate Shuttle Enhancement via Pharmacolog	0.308	metabolomics	Metabolomic signatures of neurodegenerat
Compensatory RBP Expression Therapy	0.000	-	RNA binding protein dysregulation across
Ginsenoside Rb1 Analogs for Complex I-Mediated Neuroprotecti	0.000	-	Mitochondrial transfer between astrocyte
Proteostasis Network Activation for RBPs	0.000	-	RNA binding protein dysregulation across

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (2)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
IL-10 deficiency and VLC ceramide accumulation in inflammatory bowel d	validation	inflammatory bowel disease	0.900	0.00	IL-10 knockout mice	proposed	N/A
Irisin effects on angiogenesis in human endothelial cells	exploratory	bone fracture	0.900	0.00	human umbilical vein endotheli	proposed	N/A

Related Papers (8)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Pathophysiology of Primary Familial Brain Calcification. [PMID:41212990]	Keller A	Annual review of physiology	2026
Therapeutic effects of the n-butanol extract of Potentilla freyniana Bornm. in h [PMID:40902811]	Wang Y, Zhang Z, Cao L, Huang S, Huang X	J Ethnopharmacol	2026
Based on network pharmacology and experiments to investigate the inhibitory effe [PMID:41308710]	Yang X, Xiao JH, Li X, Liu RM, Yuan Q	J Ethnopharmacol	2026
Novel insights into meningioma brain invasion with spatial transcriptomic profil [PMID:41486296]	Maier AD, Laurentiussen CO, Michaelsen S	Acta Neuropathol Commun	2026
Brain vascular stability relies on PAK2-cilia-PDGF-BB-HSPGs on basolateral side [PMID:41490797]	Prabhudesai S, Thirugnanam K, Song X, Ya	Life Sci Alliance	2026
Plasma platelet-derived growth factor receptor-β decrease correlates with blood- [PMID:41530860]	Li J, Li A, Ye C, Zhang L, Jiang M et al	Mol Neurodegener	2026
FOXF2 regulates pericyte-endothelial signaling required for vascular homeostasis [PMID:41680210]	Sun F, Zhao Y, Do J, Cheng P, Li E et al	Nat Commun	2026
Loss of Pericyte Exacerbates Alzheimer's Disease-Associated Retinal Pathology. [PMID:41814129]	Hai-Chao C, Fu-Lin G, Jia-Xin C, Yi-Shu	Clinical & experimental ophtha	2026

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning RB in their description or question text

Vascular mural cell degeneration precedes and exacerbates parenchymal pathology

Score: 0.661 · alzheimers · 2026-04-04

## Mechanistic Overview Vascular mural cell degeneration precedes and exacerbates parenchymal pathology starts from the

early PD proteogenomic hubs that are both causal enough and accessible enough to

Score: 0.626 · neurodegeneration · 2026-04-28

early PD proteogenomic hubs that are both causal enough and accessible enough to perturb should produce a measurable pro